Sandoz delivers strong H1 2025 results, with accelerated sales growth in the second quarter
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules…
Ascensia Launches Global Art Competition Exploring the Link Between Diabetes and Anxiety
Fourth annual initiative supports World Diabetes Day 2025 with patient-led creativity and…
Roche receives CE Mark for minimally invasive blood test to help rule out Alzheimers disease
Elecsys pTau181 is the first In Vitro Diagnostic Regulation (IVDR) certified test…
BioVersys and Shionogi Enter Into Global Research Collaboration For Broad-Spectrum Non-Tuberculous Mycobacteria (NTM) Clinical Candidate
July 02, 2025 01:00 ET Â | Source: BioVersys Ad hoc announcement pursuant…
Hyundai Motor Group Announces Grand Prix Recipient and Exhibitions of the 6th VH AWARD
Hyundai Motor Group premieres five commissioned artworks of the 6th VH AWARD…
Roche to advance prasinezumab into Phase III development for early-stage Parkinson’s disease
Results from Phase IIb PADOVA and longer term follow-up data suggest clinical…
![[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys gene therapy for Duchenne muscular dystrophy in non-ambulatory patients](https://i1.wp.com/ml-eu.globenewswire.com/media/NTJlMDkyZjktNGMwNi00N2YyLTkyZmQtZTIwMWJlNzgxOWYyLTEwMTI2MjEtMjAyNS0wNi0xNS1lbg==/tiny/F-Hoffmann-La-Roche-Ltd.png?w=420&resize=420,280&ssl=1 "[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys gene therapy for Duchenne muscular dystrophy in non-ambulatory patients")
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys gene therapy for Duchenne muscular dystrophy in non-ambulatory patients
After a thorough clinical review, the benefit-risk for the use of Elevidys…
Roches Evrysdi tablet approved by European Commission as first and only for Spinal Muscular Atrophy (SMA)
Simplified storage and administration of new tablet formulation may provide greater freedom…
Roches Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer
46% reduction in the risk of disease progression or death, and 27%…
Novartis Pluvicto demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition…